Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites
Objective This prospective, dose-escalation phase I study evaluated the safety and efficacy of intraperitoneal bevacizumab in managing refractory malignant ascites and explored the recommended dose of bevacizumab for further study. Methods Patients with refractory malignant ascites were enrolled. Be...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-02-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/0300060520986664 |